Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$75.78 USD

75.78
9,237,060

-0.66 (-0.86%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $75.78 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should Vanguard MidCap Growth ETF (VOT) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VOT

Zacks Equity Research

Should Vanguard MidCap ETF (VO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VO

Zacks Equity Research

Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IMCB

Riya Anand headshot

4 Internet of Medical Things (IoMT) Stocks to Buy for 2022

by Riya Anand

Stocks like Boston Scientific (BSX), Medtronic (MDT), DexCom (DXCM) and Syneos Health (SYNH) are evolving rapidly in the field of IoMT.

Zacks Equity Research

Here's Why You Should Retain DexCom (DXCM) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Zacks Equity Research

Should iShares Morningstar MidCap Growth ETF (IMCG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IMCG

Zacks Equity Research

Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWP

Zacks Equity Research

Cooper Companies' (COO) Buyout to Boost Women's Healthcare

by Zacks Equity Research

Cooper Companies' (COO) agrees to acquire Generate Life Sciences. It will be an important addition to the former's present offerings, while improving women's healthcare.

Zacks Equity Research

Should Vanguard MidCap Growth ETF (VOT) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VOT

Zacks Equity Research

Earnings Estimates Rising for DexCom (DXCM): Will It Gain?

by Zacks Equity Research

DexCom (DXCM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Company News for Nov 1, 2021

by Zacks Equity Research

Companies In The News Are: DXCM, RSG, ABBV, CVX.

Zacks Equity Research

DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) third-quarter results benefit from domestic and international revenue growth and solid new customer additions.

Zacks Equity Research

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 43.55% and 6.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should Vanguard MidCap ETF (VO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VO

Zacks Equity Research

Is a Surprise Coming for DexCom (DXCM) This Earnings Season?

by Zacks Equity Research

DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Capital One Financial, Thermo Fisher Scientific, Aflac, DexCom and Exxon Mobil

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Capital One Financial, Thermo Fisher Scientific, Aflac, DexCom and Exxon Mobil

Zacks Equity Research

Catalent (CTLT) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q1 results.

Nalak Das headshot

5 S&P 500 Stocks to Buy Ahead of Q3 Earnings This Week

by Nalak Das

Five big S&P 500 companies (market capital > $45 billion) are slated to release third-quarter earnings results this week. These are: COF, DXCM, XOM, AFL and TMO.

Zacks Equity Research

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the third quarter despite the ongoing pandemic-led business challenges.

Zacks Equity Research

Avantor (AVTR) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Avantor (AVTR) is likely to have gained during the third quarter on the back of robust performance of its end markets.

Zacks Equity Research

Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.

Zacks Equity Research

DexCom (DXCM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) third-quarter results are likely to reflect continued strength across its business segments.

Zacks Equity Research

DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

Zacks Equity Research

Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.